Inhibiting the Akt pathway in cancer treatment: Three leading candidates

P and T

Volumn 36, Issue 4, 2011, Pages 225-227

  Alexander, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CAPECITABINE; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GSK 21417195; LAPATINIB; LENALIDOMIDE; MK 2206; PERIFOSINE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG MECHANISM; HUMAN; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOLID TUMOR; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79955745338     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Pal SK. Akt inhibitors in clinical development for the treatment of cancer. Exp Opin Investig Drugs 2010;19(11):1355-1366.
2. R&D review for investors and analysts. New York, December 14, 2010.
3. Vukelja S, Richards R, Campos LT, et al. Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer (Abstract 4081). J Clin Oncol 2009;27(Suppl):15S.
4. Jakubowiak A. Final phase I results of perifosine in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract 3064). Poster, American Society of Hematology, 52nd Annual Meeting and Exposition, December 4-7, 2010.
5. Richardson P, et al. A phase I/II study evaluating the safety and efficacy of perifosine + bortezomib ± dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma who were previously treated with bortezomib. American Society of Hematology, 52nd Annual Meeting and Exposition, December 4-7, 2010.
6. Friedman DR. Pre-clinical and interim results of a phase II trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) (Abstract 1842). American Society of Hematology, 52nd Annual Meeting and Exposition, December 4-7, 2010.
7. Carlo-Stella C. Clinical activity and safety of the combined therapy with the Akt inhibitor perifosine and the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory lymphomas: Preliminary results of a phase II trial (Abstract 2861). American Society of Hematology, 52nd Annual Meeting and Exposition, December 4-7, 2010.
8. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel Akt inhibitor perifosine in relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res, January 26, 2010 (online).
9. A phase I, open-label, first-time-in-human study of the oral AKT inhibitor GSK2141795. Updated March 3, 2011. Available at: www.clinicaltrials.gov/ct2/show/NCT00920257. Accessed March 7, 2011.